245 related articles for article (PubMed ID: 29856598)
1. Detoxification of Trimethylamine N-Oxide by the Mitochondrial Amidoxime Reducing Component mARC.
Schneider J; Girreser U; Havemeyer A; Bittner F; Clement B
Chem Res Toxicol; 2018 Jun; 31(6):447-453. PubMed ID: 29856598
[TBL] [Abstract][Full Text] [Related]
2. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3.
Lang DH; Yeung CK; Peter RM; Ibarra C; Gasser R; Itagaki K; Philpot RM; Rettie AE
Biochem Pharmacol; 1998 Oct; 56(8):1005-12. PubMed ID: 9776311
[TBL] [Abstract][Full Text] [Related]
3. Reduction of sulfamethoxazole hydroxylamine (SMX-HA) by the mitochondrial amidoxime reducing component (mARC).
Ott G; Plitzko B; Krischkowski C; Reichmann D; Bittner F; Mendel RR; Kunze T; Clement B; Havemeyer A
Chem Res Toxicol; 2014 Oct; 27(10):1687-95. PubMed ID: 25170804
[TBL] [Abstract][Full Text] [Related]
4. The fourth mammalian molybdenum enzyme mARC: current state of research.
Havemeyer A; Lang J; Clement B
Drug Metab Rev; 2011 Nov; 43(4):524-39. PubMed ID: 21942410
[TBL] [Abstract][Full Text] [Related]
5. The mitochondrial Amidoxime Reducing Component (mARC) is involved in detoxification of N-hydroxylated base analogues.
Krompholz N; Krischkowski C; Reichmann D; Garbe-Schönberg D; Mendel RR; Bittner F; Clement B; Havemeyer A
Chem Res Toxicol; 2012 Nov; 25(11):2443-50. PubMed ID: 22924387
[TBL] [Abstract][Full Text] [Related]
6. The involvement of mitochondrial amidoxime reducing components 1 and 2 and mitochondrial cytochrome b5 in N-reductive metabolism in human cells.
Plitzko B; Ott G; Reichmann D; Henderson CJ; Wolf CR; Mendel R; Bittner F; Clement B; Havemeyer A
J Biol Chem; 2013 Jul; 288(28):20228-37. PubMed ID: 23703616
[TBL] [Abstract][Full Text] [Related]
7. The mammalian molybdenum enzymes of mARC.
Ott G; Havemeyer A; Clement B
J Biol Inorg Chem; 2015 Mar; 20(2):265-75. PubMed ID: 25425164
[TBL] [Abstract][Full Text] [Related]
8. The mitochondrial amidoxime reducing component (mARC): involvement in metabolic reduction of N-oxides, oximes and N-hydroxyamidinohydrazones.
Jakobs HH; Froriep D; Havemeyer A; Mendel RR; Bittner F; Clement B
ChemMedChem; 2014 Oct; 9(10):2381-7. PubMed ID: 25045021
[TBL] [Abstract][Full Text] [Related]
9. Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk.
Zhu W; Buffa JA; Wang Z; Warrier M; Schugar R; Shih DM; Gupta N; Gregory JC; Org E; Fu X; Li L; DiDonato JA; Lusis AJ; Brown JM; Hazen SL
J Thromb Haemost; 2018 Sep; 16(9):1857-1872. PubMed ID: 29981269
[TBL] [Abstract][Full Text] [Related]
10. The Involvement of the Mitochondrial Amidoxime Reducing Component (mARC) in the Reductive Metabolism of Hydroxamic Acids.
Ginsel C; Plitzko B; Froriep D; Stolfa DA; Jung M; Kubitza C; Scheidig AJ; Havemeyer A; Clement B
Drug Metab Dispos; 2018 Oct; 46(10):1396-1402. PubMed ID: 30045842
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial amidoxime-reducing component 2 (MARC2) has a significant role in
Rixen S; Havemeyer A; Tyl-Bielicka A; Pysniak K; Gajewska M; Kulecka M; Ostrowski J; Mikula M; Clement B
J Biol Chem; 2019 Nov; 294(46):17593-17602. PubMed ID: 31554661
[TBL] [Abstract][Full Text] [Related]
12. Reduction of N-hydroxy-sulfonamides, including N-hydroxy-valdecoxib, by the molybdenum-containing enzyme mARC.
Havemeyer A; Grünewald S; Wahl B; Bittner F; Mendel R; Erdélyi P; Fischer J; Clement B
Drug Metab Dispos; 2010 Nov; 38(11):1917-21. PubMed ID: 20699408
[TBL] [Abstract][Full Text] [Related]
13. Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2.
Sparacino-Watkins CE; Tejero J; Sun B; Gauthier MC; Thomas J; Ragireddy V; Merchant BA; Wang J; Azarov I; Basu P; Gladwin MT
J Biol Chem; 2014 Apr; 289(15):10345-10358. PubMed ID: 24500710
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of human mARC1 reveals its exceptional position among eukaryotic molybdenum enzymes.
Kubitza C; Bittner F; Ginsel C; Havemeyer A; Clement B; Scheidig AJ
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):11958-11963. PubMed ID: 30397129
[TBL] [Abstract][Full Text] [Related]
15. Dioxin-like pollutants increase hepatic flavin containing monooxygenase (FMO3) expression to promote synthesis of the pro-atherogenic nutrient biomarker trimethylamine N-oxide from dietary precursors.
Petriello MC; Hoffman JB; Sunkara M; Wahlang B; Perkins JT; Morris AJ; Hennig B
J Nutr Biochem; 2016 Jul; 33():145-53. PubMed ID: 27155921
[TBL] [Abstract][Full Text] [Related]
16. Interindividual Variability and Differential Tissue Abundance of Mitochondrial Amidoxime Reducing Component Enzymes in Humans.
Ahire D; Basit A; Christopher LJ; Iyer R; Leeder JS; Prasad B
Drug Metab Dispos; 2022 Mar; 50(3):191-196. PubMed ID: 34949674
[TBL] [Abstract][Full Text] [Related]
17. Dietary phenolics and their microbial metabolites are poor inhibitors of trimethylamine oxidation to trimethylamine N-oxide by hepatic flavin monooxygenase 3.
Iglesias-Carres L; Chadwick-Corbin SA; Sweet MG; Neilson AP
J Nutr Biochem; 2023 Oct; 120():109428. PubMed ID: 37549832
[TBL] [Abstract][Full Text] [Related]
18. Trimethylamine
Canyelles M; Tondo M; Cedó L; Farràs M; Escolà-Gil JC; Blanco-Vaca F
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347638
[TBL] [Abstract][Full Text] [Related]
19. The mitochondrial amidoxime reducing component-from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target.
Struwe MA; Scheidig AJ; Clement B
J Biol Chem; 2023 Nov; 299(11):105306. PubMed ID: 37778733
[TBL] [Abstract][Full Text] [Related]
20. The mitochondrial amidoxime-reducing component (mARC1) is a novel signal-anchored protein of the outer mitochondrial membrane.
Klein JM; Busch JD; Potting C; Baker MJ; Langer T; Schwarz G
J Biol Chem; 2012 Dec; 287(51):42795-803. PubMed ID: 23086957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
